Oculis Holding AG
OCS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001953530
No open-market purchases or sales by Oculis Holding AG insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $322.0M in total; no superinvestor holds it.
Other share classesOCSAW
13F holders, Q2 2023
Institutional positions in Oculis Holding AG as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 9
- +2 vs. Q1 2023
- Shares held
- 3.13M
- +1.78K (+0.1%) vs. Q1 2023
- Total value
- $38.5M
- +$15.3M (+66.2%) vs. Q1 2023
- New holders
- 3
- 0 more added
- Sold out
- 1
- 1 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting OCS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 59 | $322.0M |
| Q1 2026 | 57 | $534.7M |
| Q4 2025 | 41 | $363.8M |
| Q3 2025 | 20 | $191.7M |
| Q2 2025 | 23 | $99.1M |
| Q1 2025 | 20 | $94.7M |
| Q4 2024 | 12 | $59.4M |
| Q3 2024 | 10 | $36.9M |
| Q2 2024 | 11 | $39.8M |
| Q1 2024 | 9 | $40.9M |
| Q4 2023 | 7 | $44.3M |
| Q3 2023 | 9 | $32.1M |
| Q2 2023 | 9 | $38.5M |
| Q1 2023 | 7 | $23.2M |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Oculis Holding AG; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 2,381,196 | $29.4M | 9.68% | 00.0% | Unchanged |
| Nan Fung Group Holdings Ltd | 651,100 | $8.03M | 5.13% | 00.0% | Unchanged |
| Compagnie Lombard Odier SCmA | 65,000 | $804.0K | 0.02% | 00.0% | Unchanged |
| Ergoteles LLC | 20,000 | $247.4K | 0.01% | +20,000 | New |
| Bank of America Corp | 4,000 | $49.3K | 0.00% | +4,000 | New |
| Barclays PLC | 3,602 | $44.4K | 0.00% | +3,602 | New |
| Elequin Capital LP | 300 | $3.70K | 0.00% | 00.0% | Unchanged |
| DuPont Capital Management Corp | 4 | $49 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 2 | $25 | 0.00% | −1,210−99.8% | Reduced |
| HRT Financial LP | 0 | $0 | 0.00% | −24,609−100.0% | Sold out |